Cargando…
Phase II study of rhizoxin in squamous cell head and neck cancer. The EORTC Early Clinical Trials Group.
To test the anti-tumour activity of rhizoxin in recurrent and/or metastatic squamous cell head and neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and neck cancer. Patients could only have received one prior chemotherapy. Patients were entere...
Autores principales: | Verweij, J., Wanders, J., Gil, T., Schöffski, P., Catimel, G., te Velde, A., de Mulder, P. H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1996
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074424/ https://www.ncbi.nlm.nih.gov/pubmed/8562350 |
Ejemplares similares
-
Phase II clinical trials with rhizoxin in breast cancer and melanoma. The EORTC Early Clinical Trials Group.
por: Hanauske, A. R., et al.
Publicado: (1996) -
Single agent activity of rhizoxin in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group.
por: Kaplan, S., et al.
Publicado: (1996) -
Multicentre phase II pharmacological evaluation of rhizoxin. Eortc early clinical studies (ECSG)/pharmacology and molecular mechanisms (PAMM) groups.
por: McLeod, H. L., et al.
Publicado: (1996) -
Phase II trials of rhizoxin in advanced ovarian, colorectal and renal cancer.
por: Kerr, D. J., et al.
Publicado: (1995) -
Docetaxel (Taxotere) is active in non-small-cell lung cancer: a phase II trial of the EORTC Early Clinical Trials Group (ECTG)
por: Cerny, T., et al.
Publicado: (1994)